trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['impact,(-impacte),(-impacti),(-impactf)', 'breast', 't-dxd']
 not a practice-changing #esmo22 in breast onc . is it truth? not such as t-dxd in her2-low.true !! but data showed do impact daily!! 1 ddct not negotiable 2 extended-et? yes, but 5y to many pts mt-esr1 benefit from serds.should we test routinely esr-1 before et? 
?????Oncologista no @hospitalalemao-especializado em câncer de mama,???????????pai do Alê e Gui,marido da Monique. ??Torcedor do Corinthians e ??NE Patriots fan